Status:
COMPLETED
Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation
Lead Sponsor:
Andres Iñiguez Romo
Conditions:
Symptomatic Aortic Stenosis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The narrowing of the aortic valve, which prevents blood from reaching the entire body correctly is a common disease in our environment. To correct this problem, many patients undergo Transcatheter Aor...
Eligibility Criteria
Inclusion
- Diagnosed with severe symptomatic aortic stenosis
- Accepted for transfemoral TAVI by a Heart Team decision
- Evaluation of platelet reactivity assessed by VerifyNow® assay prior TAVI
Exclusion
- Contraindication to TAVI
- TAVI performed by a different access route than transfemoral
- Ned for oral anticoagulation therapy
- History of intracranial hemorrhage
- Ischemic stroke the 14 days before TAVI
- Active pathological bleeding or diathesis
- Moderate to severe hepatic impairment
- Use of strong CYP34A inhibitors or inducers
- Contraindications to DAPT for 3 months
- Contraindication to clopidogrel or ticagrelor
- Platelet count \<50,000
- Pregnancy or breastfeeding
Key Trial Info
Start Date :
June 23 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 28 2022
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04331145
Start Date
June 23 2020
End Date
February 28 2022
Last Update
March 2 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Alvaro Cunqueiro
Vigo, Pontevedra, Spain, 36312